ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · IEX Real-Time Price · USD
17.56
+1.78 (11.28%)
At close: May 7, 2024, 4:00 PM
17.60
+0.04 (0.23%)
After-hours: May 7, 2024, 7:00 PM EDT
ALX Oncology Holdings Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ALXO stock have an average target of 19.67, with a low estimate of 14 and a high estimate of 27. The average target predicts an increase of 12.02% from the current stock price of 17.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ALXO stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +13.90% | Apr 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $20 | Strong Buy | Maintains | $18 → $20 | +13.90% | Mar 11, 2024 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $10 → $14 | Strong Buy → Hold | Downgrades | $10 → $14 | -20.27% | Mar 8, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 → $21 | Buy | Maintains | $11 → $21 | +19.59% | Mar 8, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.34
from -3.74
EPS Next Year
-2.88
from -3.34
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 22.4M | 147.2M | 454.3M |
| Avg | n/a | n/a | 13.9M | 82.9M | 244.0M |
| Low | n/a | n/a | n/a | 15.1M | 67.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 961.6% | 447.9% |
| Avg | - | - | - | 498.2% | 194.3% |
| Low | - | - | - | 8.9% | -18.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.94 | -2.27 | -1.96 | -2.07 | 0.24 |
| Avg | -3.34 | -2.88 | -2.74 | -2.01 | 0.23 |
| Low | -3.92 | -3.55 | -3.23 | -1.93 | 0.23 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.